Sarepta Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SRPT research report →
Range $17 – $27
Price Chart
About the company
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to the discovery and advancement of genetic treatment modalities, including RNA-targeted therapeutics and gene therapies, specifically for rare diseases. The company currently offers two approved treatments: EXONDYS 51, prescribed for Duchenne muscular dystrophy (DMD) patients with confirmed dystrophin gene mutations amenable to exon 51 skipping, and VYONDYS 53, for DMD patients with exon 53 skipping mutations.
- CEO
- Michael E. Severino
- IPO
- 1997
- Employees
- 835
- HQ
- Cambridge, MA, US
Get TickerSpark's AI analysis on SRPT
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.43B
- P/E
- 164.11
- Fwd P/E
- 5.41
- PEG
- 0.33
- P/S
- 0.81
- P/B
- 1.02
- EV/EBITDA
- 13.94
- Div Yield
- 0.00%
- Gross Margin
- 56.25%
- Op Margin
- -2.50%
- Net Margin
- 0.75%
- ROE
- 1.04%
- ROIC
- -0.72%
Latest fiscal year · YoY change
- Revenue
- $2.20B+15.6%
- Gross Profit
- $1.32B-16.8%
- Op Income
- $-657,772,000
- Net Income
- $-713,410,000-403.3%
- EPS
- $-7.13-388.7%
- OCF Growth
- +0.1%
- FCF Growth
- +12.8%
- 52W High
- $24.68
- 52W Low
- $13.25
- 50D MA
- $18.04
- 200D MA
- $18.40
- Beta
- 0.20
- RSI (14)
- 25
- Avg Volume
- 2.69M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Sarepta said third-quarter revenue was pressured by lower ELEVIDYS sales, but PMO strength, cash generation, and a stabilizing gene therapy business allowed it to raise the low end of 2026 revenue guidance and keep advancing its DM1/FSHD pipeline.· November 5, 2026
- Total revenue was $381 million in Q3, with product revenue of $324 million and collaboration/other revenue of $58 million; EPS was not stated in the transcript.
- ELEVIDYS revenue was $83 million and PMO revenue was $240 million; management said ELEVIDYS demand stabilized versus Q2 and enrollment forms were in line with last quarter.
- Sarepta raised 2026 total net product revenue guidance to $1.25 billion-$1.3 billion and narrowed full-year combined non-GAAP R&D and SG&A guidance to $800 million-$825 million.
- Cash investments ended the quarter at nearly $1 billion, and management said the base business generated nearly $300 million of cash year-to-date, excluding Arrowhead collaboration payments.
- The company is preparing registrational programs for DM1 and FSHD, with upcoming MAD data expected in the coming weeks and FDA discussions to follow in the new year.
Q3 2026 total product revenues were $324 million, down 13% year over year. Collaboration and other revenues were $58 million, bringing total revenues to $381 million, down 5% year over year. For the first nine months of 2026, total product revenues were $983 million, down 34%; collaboration and other revenues were $530 million versus $251 million a year ago; and total revenues were approximately $1.5 billion, down 14% year over year. Gross margin commentary focused on product revenue gross margins rather than GAAP gross margin: product revenue gross margins were 59% in Q3 and 72% year to date, with a $52 million take-or-pay charge that impacted margins by about 19% in the quarter. GAAP operating loss was $9 million and non-GAAP operating profit was $23 million in Q3. Cash investments increased $54 million in the quarter to nearly $1 billion. Forward guidance: 2026 total net product revenue guidance was raised to $1.25 billion-$1.3 billion, ELEVIDYS Q4 revenue is expected to trend in line with Q3, and full-year combined non-GAAP R&D and SG&A guidance was narrowed to $800 million-$825 million.
Mike Severino said his first 90 days confirmed Sarepta’s core strengths: a commercial Duchenne franchise, a pipeline with potential differentiation in DM1 and FSHD, and enough financial strength to fund development from commercial cash flow. He emphasized that the immediate commercial priority is stabilizing ELEVIDYS while reinforcing the broader Duchenne franchise, and that the pipeline work is being advanced with urgency but also flexibility as the regulatory landscape evolves. His tone was measured and constructive, stressing “focused optimism,” execution discipline, and a desire to be judged on results rather than promises.
Ryan Wong highlighted that Sarepta delivered non-GAAP profitability and continued to generate cash despite lower product sales. He cited Q3 total product revenue of $324 million, a 13% decline year over year, and total revenues of $381 million, down 5%, while noting cost of sales of $189 million and a $52 million take-or-pay charge tied to non-cancel manufacturing obligations. He said combined non-GAAP R&D and SG&A expenses were $169 million in Q3, down 40% year over year, and that cash investments ended near $1 billion, with nearly $300 million of cash generated year to date from the base business excluding Arrowhead collaboration payments. He also pointed to narrowed full-year expense guidance of $800 million-$825 million and said capital allocation will remain focused on flexibility ahead of the 2027 notes maturity and funding DM1 and FSHD pivotal work.
Analysts focused heavily on ELEVIDYS demand recovery, the decision to end ENVISION, and how the company plans to design DM1 and FSHD pivotal studies. Management said the most resonant ELEVIDYS messages are the long-term data and the eight-to-12-year-old results, while admitting changing prescribing behavior will take time and repeated physician engagement. On ENVISION, Mike Severino said it was not part of the plan to return to the non-ambulatory population; instead, ENDEAVOR Cohort eight and its sirolimus-based safety mitigation strategy are the key data package. For DM1/FSHD, management said the upcoming MAD data should support registrational planning, with greater knockdown viewed as better, accelerated approval still considered possible, and endpoint/population selection to be informed by regulators and external natural-history data. They also said the siRNA programs are being readied for phase III manufacturing and operational readiness before the data are fully unblinded.
The quarter showed that Sarepta can still generate meaningful cash and operate profitably while funding a pipeline. Management said ELEVIDYS demand has stabilized, PMO remains strong, and long-term clinical data are resonating with physicians and families. The upcoming DM1 and FSHD readouts, plus planned regulatory engagement, give the company multiple near-term catalysts.
Revenue is still being pressured by lower ELEVIDYS sales, and management acknowledged quarter-to-quarter variability in a one-time gene therapy. The company also chose not to resume ENVISION, leaving the non-ambulatory ELEVIDYS path dependent on ENDEAVOR Cohort eight and subsequent FDA discussions. On the pipeline side, management openly discussed uncertainty around the best endpoints, populations, and design for DM1 and FSHD, and noted that meaningful functional readouts will take larger, longer studies.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 95.1%
- Shares Outstanding
- 107.24M
- Float Shares
- 101.98M
of shares held by institutions
351 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for SRPT, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Gilbert CisnerosHouse · CA31 | Sell | Apr 14, 25 | Filing → |
| Josh GottheimerHouse · NJ05 | Buy | Jul 14, 23 | Filing → |
| Josh GottheimerHouse · NJ05 | Sell | Jun 13, 23 | Filing → |
| Daniel GoldmanHouse · NY10 | Sell | Apr 10, 23 | Filing → |
| Josh GottheimerHouse · NJ05 | Buy | Mar 6, 23 | Filing → |
| Daniel GoldmanHouse · NY10 | Buy | Mar 6, 23 | Filing → |
| Daniel GoldmanHouse · NY10 | Sell | Jan 31, 23 | Filing → |
| Josh GottheimerHouse · NJ05 | Sell | Nov 6, 20 | Filing → |
| Gilbert CisnerosHouse · CA31 | Buy | Sep 14, 20 | Filing → |
| Gilbert CisnerosHouse · CA31 | Sell | Jun 10, 20 | Filing → |
| Josh GottheimerHouse · NJ05 | Buy | Dec 13, 19 | Filing → |
| Gilbert CisnerosHouse · CA39 | Buy | Oct 11, 19 | Filing → |
| Gilbert CisnerosHouse · CA39 | Buy | Oct 10, 19 | Filing → |
| Gilbert CisnerosHouse · CA39 | Buy | Apr 9, 19 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 18.78M | ▼ 219.20K |
| Vanguard Group Inc | 11.81M | ▲ 993.28K |
| Vanguard Portfolio Management LLC | 8.70M | ▲ 320.05K |
| State Street Corp | 7.41M | ▼ 1.50M |
| First Trust Advisors LP | 4.92M | ▲ 557.07K |
| Vanguard Capital Management LLC | 4.60M | ▲ 7.12K |
| Two Sigma Investments, LP | 4.60M | ▲ 5.54K |
| Aqr Capital Management LLC | 4.33M | ▼ 2.11M |
| Geode Capital Management, LLC | 2.69M | ▼ 85.25K |
| Erste Asset Management Gmbh | 2.27M | ▼ 300.00K |
| Two Sigma Advisers, LP | 2.07M | ▲ 113.30K |
| Bank Of America Corp | 2.06M | ▼ 89.94K |
Held by 496 ETFs
Biggest fund positions in SRPT by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 4, 26 | Wong Ryan Ho-Yan | other | 13,272 |
| Sep 4, 26 | Estepan Ian Michael | other | 24,799 |
| Sep 4, 26 | Rothfuss Cristin | other | 22,025 |
| Sep 4, 26 | Rodino-Klapac Louise | other | 21,423 |
| Jul 28, 26 | SEVERINO MICHAEL | other | 2,224,342 |
| Jul 28, 26 | SEVERINO MICHAEL | other | 756,104 |
| Jul 28, 26 | SEVERINO MICHAEL | other | 0 |
| Jun 4, 26 | Boor Kathryn Jean | other | 16,875 |
| Jun 4, 26 | Mayo Stephen | other | 16,875 |
| Jun 4, 26 | Wigzell Hans Lennart Rudolf | other | 16,875 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our SRPT coverage
Recent articles, reports, and earnings notes.
Want a deeper read on SRPT?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Buy, Sell, or Hold? Tuesday’s Top Upgrades and Downgrades: Cloudflare, Deckers Outdoors, DraftKings, MongoDB, Nike, Oneok, Philip Morris International, Riot Platforms, Wix.com, and More
247wallst.com · Nov 10
Sarepta Therapeutics Sees Transformational 2027 as Rare Disease Programs Advance
marketbeat.com · Nov 9
Sarepta Therapeutics, Inc. (SRPT) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 7
SRPT Q3 Earnings Miss Estimates, Stock Down as Elevidys Sales Decline
zacks.com · Nov 6
Sarepta Therapeutics Q3 Earnings Call Highlights
marketbeat.com · Nov 6
Compared to Estimates, Sarepta Therapeutics (SRPT) Q3 Earnings: A Look at Key Metrics
zacks.com · Nov 5
Sarepta Therapeutics Announces Third Quarter 2026 Financial Results and Recent Corporate Developments
businesswire.com · Nov 5
Sarepta Therapeutics (SRPT) Earnings Expected to Grow: Should You Buy?
zacks.com · Oct 29
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
